Medication Description: Zalcitabine (Zalcitabin)
2 ′, 3′-dideoxycytidine.
Synonym: Hivid, Hivid.
White or off-white crystalline powder. Soluble in water.
Active against HIV-1 and HIV-2. The mechanism of action is close to stavudine and other nucleos drugs (in the cells of the body it is phosphorylated to dideoxycytidine-5′-triphosphate).
When ingestion is well absorbed, bioavailability is at least 80%, C max - 0.8 h, T Ѕ - 1-3 h; undergoes minor biotransformation in the liver, excreted by the kidneys.
Applied with HIV infection in adults.
Assign inside 0.75 mg 3 times a day.
Possible side effects: dyspeptic symptoms, anorexia, ulcers of the esophagus and rectum, impaired liver and kidney function, jaundice, impaired vision and hearing, tachycardia, cardiomyopathy, tremor, convulsions, sleep disturbance, alopecia, anemia, leukopenia, thrombocytopenia, etc.
Contraindications: peripheral neuropathy, erosive-ulcerative esophagitis, pancreatitis, severe disorders of the liver and kidneys, cardiomyopathy, severe heart failure, pregnancy, breast-feeding, age up to 13 years.
Product form: tablets of 0.375 and 0.75 mg (N. 20, 100).
Storage: List B.